Daniel Ciznadija

Daniel Ciznadija, PhD, currently serves as the Director at Champions Oncology, Inc., where responsibilities include driving projects focused on understanding molecular and clinical data related to patient-derived xenograft (PDX) models, and enhancing the analytical pipeline through the application of advanced statistical tools. Previous roles include Senior Scientist and Science and Medical Writer, where collaboration with academic and industrial partners was paramount to advancing TumorGraft technology. Prior experience at Memorial Sloan-Kettering Cancer Center involved leading research on the implications of pharmacological inhibition in brain tumor formation, while earlier positions at Sienna Cancer Diagnostics and Peter MacCallum Cancer Centre contributed to the development of biomarker assays and understanding the signaling pathways in colon cancer, respectively. Academic credentials include a Ph.D. in Cellular and Molecular Biology from the University of Melbourne and a BSc (Hons) in Biochemistry and Chemistry from Monash University. Key skills encompass various techniques in cell biology and mouse tumor modeling.